MedTrace Logo

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05954988 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.

Conditions

Interventions

DRUG

LTI-03

Caveolin-1-Scaffolding-Protein-Derived Peptide

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Rein Therapeutics

    lead INDUSTRY

Principal Investigators

  • Steven A. Shoemkaer, MD · Lung Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2024-09-25
Completion
2024-09-25
FDA Drug
Yes

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05954988 on ClinicalTrials.gov